| Literature DB >> 24102146 |
Sara Stridh1, Fredrik Palm, Peter Hansell.
Abstract
BACKGROUND: Hyaluronan (HA) is the dominant glycosaminoglycan in the renomedullary interstitium. Renomedullary HA has been implicated in tubular fluid handling due to its water-attracting properties and the changes occurring in parallel to acute variations in the body hydration status.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24102146 PMCID: PMC4190891 DOI: 10.3109/03009734.2013.834013
Source DB: PubMed Journal: Ups J Med Sci ISSN: 0300-9734 Impact factor: 2.384
Figure 1.Hyaluronan (HA) content in cortex and inner medulla (papilla) in control rats and in rats treated with the hyaluronan synthesis inhibitor 4-MU. *p < 0.05 versus control.
Glomerular filtration rate (GFR), mean arterial blood pressure (MAP), urine flow rate, and sodium excretion in control rats (C) and in rats treated with the hyaluronan synthesis inhibitor 4-MU. Each period corresponds to 45 min in consecutive order, p < 0.05 versus Control period of same group. Values are means ± SEM.
| Control period | Hydration 1 | Hydration 2 | Hydration 3 | |
|---|---|---|---|---|
| GFR (mL/min/g kw) | ||||
| C | 0.90 ± 0.27 | 0.78 ± 0.22 | 0.93 ± 0.16 | 0.90 ± 0.10 |
| 4-MU | 0.84 ± 0.12 | 0.65 ± 0.12 | 0.80 ± 0.15 | 0.82 ± 0.15 |
| MAP (mmHg) | ||||
| C | 109 ± 11 | 104 ± 11 | 108 ± 9 | 105 ± 8 |
| 4-MU | 97 ± 4 | 96 ± 4 | 96 ± 3 | 92 ± 3 |
| Urine flow rate (µL/min/g kw) | ||||
| C | 1.31 ± 0.45 | 1.59 ± 0.32 | 2.61 ± 0.89 | 2.54 ± 0.49 ( |
| 4-MU | 0.82 ± 0.13 | 1.16 ± 0.34 | 1.48 ± 0.41 | 1.52 ± 0.30 ( |
| Sodium excretion (µL/min/g kw) | ||||
| C | 0.05 ± 0.01 | 0.07 ± 0.02 | 0.08 ± 0.02 | 0.07 ± 0.05 |
| 4-MU | 0.07 ± 0.02 | 0.06 ± 0.02 | 0.06 ± 0.02 | 0.07 ± 0.02 |
kw = kidney weight.
Figure 2.Accumulated urine excretion during hydration in control rats and in rats treated with the hyaluronan synthesis inhibitor 4-MU. *p < 0.05 versus control. (kw = kidney weight).
Figure 3.Accumulated osmolar excretion during hydration in control rats and in rats treated with the hyaluronan synthesis inhibitor 4-MU. *p < 0.05 versus control. (kw = kidney weight).